The role of modulators in cystic fibrosis related diabetes

被引:26
|
作者
Merjaneh, Lina [1 ]
Hasan, Sana [2 ]
Kasim, Nader [3 ]
Ode, Katie Larson [4 ]
机构
[1] Seattle Childrens Hosp, Dept Pediat, Div Endocrinol, Seattle, WA USA
[2] Cleveland Clin Fdn, Dept Endocrinol & Metab, Cleveland, OH USA
[3] Helen Devos Childrens Hosp, Div Pediat Diabet & Endocrinol, Spectrum Hlth, Grand Rapids, MI USA
[4] Univ Iowa, Dept Pediat, Div Endocrinol, Stead Family Childrens Hosp, Iowa City, IA USA
关键词
CFRD; Modulator therapy; Insulin; INSULIN-SECRETION; TEZACAFTOR-IVACAFTOR; CHLORIDE CHANNEL; CFTR; EPIDEMIOLOGY; CHILDREN;
D O I
10.1016/j.jcte.2021.100286
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development and introduction of modulator therapies have completely shifted the paradigm for the treatment of cystic fibrosis (CF). Highly effective modulator therapies have driven marked improvements in lung function, exacerbation rate, weight and quality of life in CF patients. However, their effect on CF related diabetes (CFRD) is not well delineated. The role of CF transmembrane conductance regulator (CFTR) in CFRD pathogenesis is inadequately understood and research aimed at deciphering the underlying mechanisms of CFRD continues to evolve. In this review, we summarize what is known regarding the effect of CFTR modulators on CFRD. Small studies using ivacaftor monotherapy in gating mutations have revealed improvement in insulin secretion, glucose tolerance and/or decrease in insulin requirement. However, lumacaftor/ivacaftor studies (primarily in delta F 508 homozygous) have not revealed significant improvement in CFRD or glucose tolerance. No studies are yet available regarding the effect of the highly effective triple therapy (elexacaftor/tezacaftor/ivacaftor) on CFRD or insulin secretion. CFTR modulators might affect development or progression of CFRD through many mechanisms including improving insulin secretion by correcting the CFTR defect directly, improving ductal function, reducing islet inflammation, and improving incretin secretion or by enhancing insulin sensitivity via reduced systemic inflammation and increased physical activity driven by improved lung function and quality of life. On the other hand, they can stimulate appetite and improve gastrointestinal function resulting in increased caloric intake and absorption, driving excessive weight gain and potentially increased insulin resistance. If the defect in insulin secretion is reversible then it is possible that initiation of CFTR modulators at a younger age might help prevent CFRD. Despite the advances in CF management, CFRD remains a challenge and knowledge continues to evolve. Future studies will drive better understanding of the role of highly effective CFTR modulators in CFRD.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Infancy onset cystic fibrosis related diabetes
    Gelfand, IM
    Eugster, EA
    Haddad, NG
    DIABETES, 2005, 54 : A517 - A517
  • [42] Cystic Fibrosis Related Diabetes: A Case Report
    Yilmaz, Banu Aktas
    Kan, Erdal
    Toruner, Fusun
    Karakoc, Ayhan
    Akturk, Mujde
    Oruc, Munevver Kirci
    Arslan, Metin
    TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2012, 16 (03) : 75 - 78
  • [43] Hyperglycemia and Death in Cystic Fibrosis Related Diabetes
    Adler, Amanda I.
    Bilton, Diana
    Haworth, Charles
    Shine, Brian
    DIABETES, 2010, 59 : A505 - A505
  • [44] Treatment of cystic fibrosis-related diabetes
    Kessler, Laurence
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (03): : 167 - 167
  • [45] Physical activity in cystic fibrosis related diabetes
    Cox, Narelle
    Holland, Anne
    Alison, Jennifer
    Dwyer, Tiffany
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [46] Diabetic retinopathy in cystic fibrosis related diabetes
    Ahmed, M. S.
    Tahrani, A.
    DIABETOLOGIA, 2017, 60 : S472 - S473
  • [47] Cystic Fibrosis-Related Diabetes in Childhood
    O'Riordan, Stephen M. P.
    Dattani, Mehul T.
    Hindmarsh, Peter C.
    HORMONE RESEARCH IN PAEDIATRICS, 2010, 73 (01): : 15 - 24
  • [48] Cystic fibrosis related diabetes: Medical management
    Ode, Katie Larson
    Chan, Christine L.
    Granados, Andrea
    Moheet, Amir
    Moran, Antoinette
    Brennan, Amanda L.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 : S10 - S18
  • [49] Pharmacological management of cystic fibrosis related diabetes
    Moheet, Amir
    Moran, Antoinette
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (02) : 185 - 191
  • [50] Cystic fibrosis related diabetes (CFRD) prognosis
    Sandouk, Zahrae
    Khan, Farah
    Khare, Swapnil
    Moran, Antoinette
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2021, 26